NASDAQ:TRPX Therapix Biosciences (TRPX) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free TRPX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.09▼$0.1250-Day Range$0.10▼$0.3252-Week Range$0.25▼$4.69Volume95,212 shsAverage Volume1.59 million shsMarket Capitalization$351,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Therapix Biosciences alerts: Email Address Ad DTIweirdest stock market marches onFor the last few months, Graham Lindman has been urging investors to ignore virtually every stock on the exchange and only focus on the handful of “Apex Stocks” that produce all the wealth. And he sure seems to be right! Because while we’re in an extremely bullish market, it’s not because most companies are doing that well. It’s because a handful of wealth generating juggernauts are yanking the market to all time highs. That’s why this headline called it the “Weirdest bull market”Graham is hosting a “tell all” workshop about his Apex Indicator here About Therapix BiosciencesRead More Ad Monetary GoldDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. TRPX Stock News HeadlinesDecember 12, 2023 | benzinga.comAnixa Biosciences Stock (NASDAQ:ANIX), Analyst Ratings, Price Targets, PredictionsAugust 23, 2023 | investing.comSagimet Biosciences Inc (SGMT)August 1, 2023 | seekingalpha.comPBIO Pressure BioSciences, Inc.January 19, 2022 | thestreet.comCannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOsSee More Headlines Receive TRPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Therapix Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/20/2018Today5/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TRPX CUSIPN/A CIK1611746 Webtherapixbio.com Phone972-3616-7055FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares3,510,000Free FloatN/AMarket Cap$351,000.00 OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Ascher Shmulewitz (Age 63)Chairman & Interim CEO Dr. Adi Zuloff-Shani (Age 51)Chief Technology Officer Mr. Oz Adler CPA (Age 32)Chief Financial Officer Key CompetitorsAptevo TherapeuticsNASDAQ:APVOAmpio PharmaceuticalsNYSE:AMPEAthersysNASDAQ:ATHXChina SXT PharmaceuticalsNASDAQ:SXTCAditxtNASDAQ:ADTXView All Competitors TRPX Stock Analysis - Frequently Asked Questions How were Therapix Biosciences' earnings last quarter? Therapix Biosciences Ltd. (NASDAQ:TRPX) posted its quarterly earnings data on Monday, August, 20th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.24. What other stocks do shareholders of Therapix Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Therapix Biosciences investors own include Zynerba Pharmaceuticals (ZYNE), Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO), Tilray (TLRY), Corbus Pharmaceuticals (CRBP) and VBI Vaccines (VBIV). This page (NASDAQ:TRPX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceThe Presidential candidate you should REALLY be worried aboutStansberry Research[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Therapix Biosciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
